Mar 2, 2026 06:05AM
Jan 12, 2026 07:02AM
Jan 12, 2026 07:00AM
Dec 22, 2025 12:49AM
Dec 21, 2025 08:00PM
Dec 3, 2025 07:30AM
Dec 3, 2025 07:30AM Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology
Nov 13, 2025 04:01PM
Nov 4, 2025 07:01AM
Nov 4, 2025 07:01AM
Oct 7, 2025 07:30AM
Oct 7, 2025 07:30AM
Sep 16, 2025 09:00AM
Sep 16, 2025 09:00AM Relmada Regains Compliance with Nasdaq Minimum Bid Price Requirement
Sep 10, 2025 07:15AM
Sep 10, 2025 07:15AM
Aug 7, 2025 04:05PM
Jul 15, 2025 08:02AM
Jul 15, 2025 08:00AM
Jun 17, 2025 07:00AM
May 12, 2025 04:01PM Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Apr 28, 2025 01:39PM
Apr 28, 2025 01:38PM
Apr 27, 2025 09:00AM
Apr 24, 2025 08:00AM
Apr 14, 2025 08:41AM
Apr 14, 2025 07:30AM
Mar 27, 2025 04:05PM Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update
Mar 25, 2025 07:32AM
Mar 25, 2025 07:30AM
Feb 6, 2025 07:30AM
Feb 6, 2025 07:30AM
Jun 18, 2024 08:31AM
Jun 18, 2024 08:30AM
Jan 9, 2023 08:01AM Relmada Therapeutics (RLMD) Appoints Cedric O'Gorman as Chief Medical Officer
Jan 9, 2023 08:00AM
Sep 20, 2022 08:30AM
Aug 11, 2022 04:15PM
Aug 9, 2022 08:31AM
Aug 9, 2022 08:30AM
Feb 23, 2022 06:32AM
Feb 23, 2022 06:31AM Relmada Therapeutics Announces Top-Line Results of Study Evaluating REL-1017 vs Ketamine for Abuse Potential
Dec 1, 2021 08:30AM
Nov 11, 2021 04:01PM
Oct 29, 2021 08:34AM
Oct 4, 2021 08:32AM
Oct 4, 2021 08:30AM
Sep 13, 2021 06:06PM
Jul 27, 2021 07:35AM Relmada Therapeutics (RLMD) Announces Top-Line Results of Study Evaluating REL-1017 vs Oxycodone for Abuse Potential
Jul 27, 2021 07:35AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All